Current Diabetes Reports

, Volume 13, Issue 1, pp 89–95

Progression of β-Cell Dysfunction in Obese Youth

Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)

Abstract

The epidemic of childhood obesity has led to a remarkable increase in the prevalence of type 2 diabetes (T2D) among youth worldwide. The decreasing age at onset of T2D has alarming public health implications. In particular, the longer duration of the disease, as well as the faster onset and progression of T2D related complications, will present a considerable burden for young adults and a strain on public health. Therefore, it is important to understand the pathophysiology of early phases of disruption of glucose tolerance and identify those critical points in which diabetes may be prevented. β-Cell dysfunction has been shown to represent one of the key pathogenetic defects underlying the progression to diabetes in obese youth. In the present review, we describe longitudinal and cross-sectional studies of changes in insulin sensitivity and secretion across the spectrum of glucose tolerance in obese adolescents. Further, the role of ectopic fat accumulation is discussed in relation to its association with both β-cell dysfunction and insulin resistance.

Keywords

β-Cell dysfunction Obesity Insulin resistance Type 2 diabetes Youth 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307(5):483–90Google Scholar
  2. 2.
    Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2011;363(23):2211–9.Google Scholar
  3. 3.
    Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010;375:1737–48.Google Scholar
  4. 4.
    Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700.PubMedCrossRefGoogle Scholar
  5. 5.
    • Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67. This paper is important because the large sample size (a prospective cross-sectional study of 704 adolescents with recent-onset T2D) and ethnic/racial diversity of the TODAY study participants represents the largest and best characterized sample of American youth with recent-onset T2D. Results from this study provide the most current data on the prevalence of autoimmunity in phenotypic T2D youth in the United States and particularly show youth with type 2 diabetes are: high percentage of women; Hispanics and non-Hispanic Blacks; and present relevant baseline abnormalities including high blood pressure, low HDL, elevated triglycerides, and microalbuminuria.PubMedCrossRefGoogle Scholar
  6. 6.
    Dabelea D, Bell RA, D'Agostino Jr RB, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–24.PubMedCrossRefGoogle Scholar
  7. 7.
    Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000;23:381–9.Google Scholar
  8. 8.
    Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004;27:1798–811.PubMedCrossRefGoogle Scholar
  9. 9.
    Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003–2006. JAMA. 2008;299:2401–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003;88:1417–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Elder DA, Herbers PM, Weis T, Standiford D, Woo JG, D’Alessio DA. beta-cell dysfunction in adolescents and adults with newly diagnosed type 2 diabetes mellitus. J Pediatr. 2012;160:904–10.PubMedCrossRefGoogle Scholar
  12. 12.
    • Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369:1823–31. In this review authors described the main complications associated with type 2 diabetes in youth.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56. This paper is important because using a well characterized large population it clearly highlights the difficulty in treating this disease in the pediatric population.PubMedCrossRefGoogle Scholar
  14. 14.
    Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Baranowski T, Cooper DM, Harrell J, Hirst K, Kaufman FR, Goran M, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care. 2006;29:212–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Goran MI, Bergman RN, Avila Q, Watkins M, Ball GD, Shaibi GQ, et al. Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab. 2004;89:207–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Csabi G, Torok K, Jeges S, Molnar D. Presence of metabolic cardiovascular syndrome in obese children. Eur J Pediatr. 2000;159:91–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11:349–52.PubMedCrossRefGoogle Scholar
  19. 19.
    D'Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 2011;34 Suppl 2:S161–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005;28:902–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003;26:2871–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia. 2002;45:85–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes. 2008;57:1584–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54:1735–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Cali AM, Man CD, Cobelli C, Dziura J, Seyal A, Shaw M, et al. Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care. 2009;32:456–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Cali AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab. 2008;93:1767–73.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Giannini C, Weiss R, Cali A, Bonadonna R, Santoro N, Pierpont B, et al. Evidence for early defects in insulin sensitivity and secretion before the Onset of glucose dysregulation in obese youths: a longitudinal study. Diabetes. 2012;61:606–14. In this prospective longitudinal cohort study, authors evaluated insulin secretion by applying mathematical modeling during the hyperglycemic clamp and insulin sensitivity by hyperinsulinemic-euglycemic clamp in a group of obese NGT and IGT adolescents. In addition, glucose tolerance was reevaluated after 2 years. Data at baseline indicates that even within NGT individuals, oDI worsens as 2 h glucose tolerance test values increase. Longitudinal data shows progressors from NGT gained weight and had beta-cell defects predicting the risk of developing glucose alteration at follow up.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ. Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes. 2008;57:3007–12. In this longitudinal study, Hispanic adolescents were longitudinally evaluated in order to characterize the risk of developing type 2 Diabetes. Results showed that the persistence of impaired glucose tolerance over time represents a relevant risk factor in predicting the risk of progression.PubMedCrossRefGoogle Scholar
  33. 33.
    Tfayli H, Lee S, Arslanian S. Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in children. Diabetes Care. 2010;33:2024–30.Google Scholar
  34. 34.
    Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab. 2004;89:2590–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Arslanian S, Suprasongsin C. Insulin sensitivity, lipids, and body composition in childhood: is “syndrome X” present? J Clin Endocrinol Metab. 1996;81:1058–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care. 2006;29:2427–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003;362:951–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology. 2009;49:1896–903.PubMedCrossRefGoogle Scholar
  40. 40.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMedCrossRefGoogle Scholar
  41. 41.
    Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287–94.PubMedCrossRefGoogle Scholar
  42. 42.
    Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr. 2005;41:94–8.PubMedCrossRefGoogle Scholar
  43. 43.
    • D’Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33(8):1817–22. In this study authors well describe the role of hepatic fat accumulation in the pathogenesis of insulin resistance in obese youth. Google Scholar
  44. 44.
    Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Taksali SE, Caprio S, Dziura J, Dufour S, Cali AM, Goodman TR, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008;57:367–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B, et al. Adolescent BMI trajectory and risk of diabetes vs coronary disease. N Engl J Med. 2011;364:1315–25.PubMedCrossRefGoogle Scholar
  47. 47.
    • Morrison JA, Glueck CJ, Horn PS, Wang P. Childhood predictors of adult type 2 diabetes at 9- and 26-year follow-ups. Arch Pediatr Adolesc Med. 2010;164:53–60. In this prospective longitudinal study authors attempted to determine whether pediatric office measures (waist circumference, body mass index [BMI], systolic [SBP], and diastolic [DBP] blood pressure, and parental diabetes) and laboratory measures (glucose, triglyceride, high-density lipoprotein cholesterol, and insulin) predict risk of type 2 diabetes mellitus (T2D) at ages 19 and 39 years. By using data from 9- and 26-year prospective follow-ups of schoolchildren, authors showed that office-based childhood measures predict the presence and absence of future T2D 9 and 26 years after baseline. In addition, they showed that childhood insulin measurement improves prediction, facilitating approaches to primary prevention of T2D.PubMedCrossRefGoogle Scholar
  48. 48.
    Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115:e290–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Fernandez-Twinn DS, Ozanne SE. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav. 2006;88:234–43.PubMedCrossRefGoogle Scholar
  50. 50.
    Mayer-Davis EJ. Type 2 diabetes in youth: epidemiology and current research toward prevention and treatment. J Am Diet Assoc. 2008;108(4 Suppl 1):S45–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Kempf K, Rathmann W, Herder C. Impaired glucose regulation and type 2 diabetes in children and adolescents. Diabetes Metab Res Rev. 2008;24:427–37.PubMedCrossRefGoogle Scholar
  52. 52.
    Laitinen J, Pietilainen K, Wadsworth M, Sovio U, Jarvelin MR. Predictors of abdominal obesity among 31-y-old men and women born in Northern Finland in 1966. Eur J Clin Nutr. 2004;58:180–90.PubMedCrossRefGoogle Scholar
  53. 53.
    Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298:564–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303:1019–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990;301:259–62.PubMedCrossRefGoogle Scholar
  57. 57.
    Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. N Engl J Med. 1976;295:349–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595–601.PubMedCrossRefGoogle Scholar
  59. 59.
    Forsen T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med. 2000;133:176–82.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of PediatricsYale University School of MedicineNew HavenUSA

Personalised recommendations